|
|
|
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) |
|
|
|
| |
Vertex Pharmaceuticals Inc Outlook |
On August 2 2024 the Vertex Pharmaceuticals Inc provided following guidance
Vertex Pharmaceuticals Incorporated has announced its financial results for the second quarter of 2024, concluding on June 30. Following this robust performance, the company has revised its full-year revenue projections upward to an impressive range of $10.65 billion to $10.85 billion.
In the report, Reshma Kewalramani, M.D., who serves as the Chief Executive Officer and President of Vertex, highlighted the company's strong quarter marked by significant revenue growth and exemplary execution across various facets of the business. This positive momentum has prompted the company to adjust its revenue expectations for the year, reflecting their confidence in future performance.
Vertex continues to demonstrate its commitment to delivering innovative solutions in the biopharmaceutical sector, and this updated guidance underscores its optimistic outlook for sustained growth throughout the remainder of the year.
|
On August 1 2024 the Vertex Pharmaceuticals Inc provided following guidance
nnVertex Pharmaceuticals Inc. Updates 2024 Financial Projections and Reports Strong Q2 Resultsnn
BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced its financial performance for the second quarter, which concluded on June 30, 2024. The company has upgraded its annual product revenue expectations, now forecasting a range between $10.65 billion and $10.85 billion.
Reshma Kewalramani, M.D., the Chief Executive Officer and President of Vertex, expressed satisfaction with the company’s performance, stating, Vertex has achieved yet another impressive quarter marked by significant revenue growth and exceptional operational execution. As a result, we are pleased to adjust our full-year product revenue guidance upward.
In the second quarter, Vertex demonstrated robust financial growth and effective management across its operations, which has led to the positive revision in revenue targets for the year. The company continues to capitalize on its innovative portfolio and remains committed to delivering high-quality therapeutic solutions.
|
On May 6 2024 the Vertex Pharmaceuticals Inc provided following guidance
expansion of our pipeline, and made progress on our goal of developing transformative medicines for serious diseases, said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
For the first quarter of 2024, Vertex reported total product revenues of $1.8 billion, representing a 13 percent increase compared to the first quarter of 2023. This growth was primarily driven by strong performance of our cystic fibrosis (CF) franchise, with revenues of $1.5 billion, up 15 percent year-over-year.
Our CF franchise continues to be a key driver of growth for Vertex, and we are excited about the potential of our new triple combination therapy, vanzacaftor, which has completed regulatory submissions and has the potential to treat up to 90 percent of people with CF, said Kewalramani.
In addition to our CF franchise, Vertex also saw growth in other therapeutic areas, with revenues from our non-CF medicines reaching $300 million in the first quarter of 2024, up 5 percent from the same period last year.
Vertex also reported a net loss of $50 million for the first quarter of 2024, compared to a net income of $300 million in the first quarter of 2023. This decrease was primarily due to increased investments in research and development, as well as higher operating expenses related to the expansion of our global footprint.
Looking ahead, Vertex reiterated its full year 2024 financial guidance, expecting total product revenues to be in the range of $7.5 billion to $8 billion. The company also reaffirmed its commitment to advancing its pipeline of innovative therapies, with several key milestones expected throughout the year.
In 2024, Vertex is focused on delivering transformative medicines for patients in need, and we remain confident in our ability to drive growth and create long-term value for shareholders, said Kewalramani. We are excited about the opportunities ahead and look forward to continuing to make a meaningful impact in the lives of patients around the world.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
